Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes.

ABSTRACT:

Objective

Clinical trials suggest that SGLT2 inhibitors reduce the risk of cardiovascular mortality in patients with type 2 diabetes, however the mechanism is unclear. Our objective was to test the hypothesis that blood pressure reduction is one potential mechanism underlying the observed improvements in cardiovascular outcomes with SGLT2 inhibitors.

Methods

We searched MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials (inception-June 2019) for randomized controlled trials that reported the effect of SGLT2 inhibitors compared with placebo on cardiovascular outcomes in adults with type 2 diabetes. Two reviewers independently extracted data and assessed study quality. Random effects meta-analyses, stratified meta-analyses and meta-regressions were conducted to

SUBMITTER: Benham JL 

PROVIDER: S-EPMC7892922 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature